Ipsat Therapies

Ipsat Announces Positive Data on a Novel Therapy Designed to Reduce Healthcare-associated Infections and the Spread of Antibiotic Resistance

Older News

HELSINKI - Ipsat Therapies announced today that oral P1A beta-lactamase met all end-points and provided protection for the normal gastrointestinal microflora in a phase 1 study in healthy subjects receiving intravenous piperacillin/tazobactam for 5 days.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy